Pulmonary infections in patients with rheumatoid arthritis who have received anti-TNF therapy

Internal Medicine

Volumn 45, Issue 17, 2006, Pages 991-992

  Amano, Koichi ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Infliximab; Pneumocystis; Rheumatoid arthritis; Tuberculosis; Tumor necrosis factor

Indexed keywords

BETA GLUCAN; ETANERCEPT; GAMMA INTERFERON; GLYCOLIPID; INFLIXIMAB; ISONIAZID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

BACTERIUM DETECTION; BRONCHUS BIOPSY; CELL ACTIVATION; CELLULAR IMMUNITY; CYTOLOGY; DIAGNOSTIC ACCURACY; DISEASE TRANSMISSION; EDITORIAL; ENVIRONMENTAL EXPOSURE; EXTRAPULMONARY TUBERCULOSIS; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; JAPAN; LUNG INFECTION; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; OPPORTUNISTIC INFECTION; OSTEOCLAST; PATHOGENESIS; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SPUTUM ANALYSIS; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; OPPORTUNISTIC INFECTIONS; PNEUMOCYSTIS INFECTIONS; PNEUMOCYSTIS JIROVECI; RESPIRATORY TRACT INFECTIONS; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33749499859     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.45.0156     Document Type: Editorial

References (13)

1. Haraoui B. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis. J Rheumatol Suppl 72: 46-47, 2005.
2. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 1098-104, 2001.
3. Goḿez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48: 2122-2127, 2003.
4. Bowie VL, Snella KA, Gopalachar AS, Bharadwaj P. Listeria meningitis associated with infliximab. Ann Pharmacother 38: 58-61, 2004.
5. Tai TL, O'Rourke KP, McWeeney M, Burke CM, Sheehan K, Barry M. Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology 41: 951-952, 2002.
6. Cush JJ. Safety overview of new disease-modifying antirheumatic drugs. Rheum Dis Clin North Am 30: 237-255, 2004.
7. Imaizumi K, Sugishita M, Usui M, Kawabe T, Hashimoto N, Hasegawa Y. Pulmonary infectious complications associated with anti-TNFα therapy (Infliximab) for rheumatoid arthritis. Intern Med 45 (10): 685-688, 2006.
8. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52: 1766-1772, 2005.
9. Maekura R, Okuda Y, Nakagawa M, et al. Clinical evaluation of anti-tuberculous glycolipid immunoglobulin G antibody assay for rapid serodiagnosis of pulmonary tuberculosis. J Clin Microbiol 39: 3603-3608, 2001.
10. Ferrara G, Losi M, Meacci M, et al. Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 172: 631-635, 2005.
11. Morris A, Beard CB, Huang L. Update on the epidemiology and transmission of Pneumocystis carinii. Microbes Infect 4: 95-103, 2002,
12. Torres J, Goldman M, Wheat LJ, et al. Diagnosis of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients with polymerase chain reaction:a blinded comparison to standard methods. Clin Infect Dis 30: 141-145, 2000.
13. Shimizu A, Oka H, Matsuda T, Ozaki S. (1->3)-beta-D glucan is a diagnostic and negative prognostic marker for Pneumocystis carinii pneumonia in patients with connective tissue disease. Clin Exp Rheumatol 23: 678-680, 2005.